Other formats:
BibTeX
LaTeX
RIS
@article{1301076,
author = {Řiháček, Michal and Bienertová Vašků, Julie and Valík, Dalibor and Štěrba, Jaroslav and Pilátová, Kateřina and Zdražilová Dubská, Lenka},
article_location = {New York},
article_number = {"792187"},
doi = {http://dx.doi.org/10.1155/2015/792187},
keywords = {adipocytokine; B cell activating factor; B cell activating factor receptor; estrogen; immunoglobulin enhancer binding protein; insulin receptor; interferon},
language = {eng},
issn = {2314-6133},
journal = {Biomed Research International},
title = {B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia},
url = {http://downloads.hindawi.com/journals/bmri/aa/792187.pdf},
volume = {2015},
year = {2015}
}
TY - JOUR
ID - 1301076
AU - Řiháček, Michal - Bienertová Vašků, Julie - Valík, Dalibor - Štěrba, Jaroslav - Pilátová, Kateřina - Zdražilová Dubská, Lenka
PY - 2015
TI - B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
JF - Biomed Research International
VL - 2015
IS - "792187"
SP - 1-9
EP - 1-9
PB - HINDAWI PUBLISHING CORPORATION
SN - 23146133
KW - adipocytokine
KW - B cell activating factor
KW - B cell activating factor receptor
KW - estrogen
KW - immunoglobulin enhancer binding protein
KW - insulin receptor
KW - interferon
UR - http://downloads.hindawi.com/journals/bmri/aa/792187.pdf
N2 - B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.
ER -
ŘIHÁČEK, Michal, Julie BIENERTOVÁ VAŠKŮ, Dalibor VALÍK, Jaroslav ŠTĚRBA, Kateřina PILÁTOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia. \textit{Biomed Research International}. New York: HINDAWI PUBLISHING CORPORATION, 2015, vol.~2015, ''792187'', p.~1-9. ISSN~2314-6133. Available from: https://dx.doi.org/10.1155/2015/792187.
|
